AstraZeneca consensus stays positive, analysts see upside for shares

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 19:34.

AstraZeneca (GB0009895292) remains a core healthcare name on the London Stock Exchange, with analysts seeing further upside from current FTSE 100 levels. According to Investing.com, the consensus 12-month price target sits well above the latest London closing price.

What analysts are pricing in

The analyst community tracked by Investing.com shows a clear Buy stance on AstraZeneca, with 21 houses contributing to the consensus view on the London-listed shares. Nineteen recommend buying the stock, three advise holding and one suggests selling, resulting in an overall Buy recommendation. Analyst consensus data from Investing.com

The same overview puts the average 12-month price target at 16,681.3 pence, compared with an implied current level around 13,290 pence, which points to potential upside of roughly 22 percent for the shares if projections are met. Investing.com price-target overview

How the shares trade in London

On the London Stock Exchange, AstraZeneca trades under the ticker AZN and remains one of the heavier weights in the FTSE 100 healthcare cohort alongside peers such as GSK and Sanofi. MarketScreener puts the latest London quote at 13,290 pence as of June 22, 2026, with the stock fractionally higher on the day. MarketScreener London quote and news feed

Hargreaves Lansdown data show a market capitalization of around 206.11 billion pounds at that price level, with a trailing price-earnings ratio just above 26 and a dividend yield close to 1.8 percent, underlining the stock’s role as a large-cap growth and income blend within the FTSE 100. Hargreaves Lansdown key metrics

How AstraZeneca earns its money

AstraZeneca generates its revenue mainly from prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease lines, with a strong focus on patented therapies. Flagship products include the cancer drug Tagrisso, the immunotherapy Imfinzi and cardiovascular treatment Farxiga, alongside a pipeline of late-stage biologics and targeted therapies.

Where the AstraZeneca shares trade today

The AstraZeneca shares (GB0009895292) trade on June 22, 2026, at 13,290.00 pence on the London Stock Exchange.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. All data are based on sources believed to be reliable but cannot be guaranteed.